His main research concerns Asthma, Bronchodilator, Internal medicine, Immunology and Anesthesia. His Asthma research is multidisciplinary, relying on both Randomized controlled trial, Intensive care, Intensive care medicine, Placebo and Corticosteroid. He has researched Bronchodilator in several fields, including Leukotriene receptor, Zafirlukast, Montelukast, Leukotriene and Salmeterol.
Michael E. Wechsler interconnects Gastroenterology and Surgery in the investigation of issues within Internal medicine. He combines subjects such as Receptor, Prostaglandin D2 and Lung microbiome with his study of Immunology. He has included themes like Morning, Clinical trial and Crossover study in his Anesthesia study.
His scientific interests lie mostly in Asthma, Internal medicine, Immunology, Intensive care medicine and Clinical trial. His biological study spans a wide range of topics, including Anesthesia, Randomized controlled trial, Adverse effect, Placebo and Corticosteroid. His Anesthesia research includes elements of Crossover study, Methacholine and Bronchodilator.
Michael E. Wechsler combines topics linked to Gastroenterology with his work on Internal medicine. In his study, Granulomatosis with polyangiitis is strongly linked to Eosinophilic, which falls under the umbrella field of Immunology. His work deals with themes such as Bronchial thermoplasty and Severe asthma, which intersect with Intensive care medicine.
Asthma, Internal medicine, Intensive care medicine, Severe asthma and Reslizumab are his primary areas of study. His work on Dupilumab as part of general Asthma study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Eosinophilic.
His research investigates the link between Intensive care medicine and topics such as Clinical trial that cross with problems in Precision medicine, Family medicine and Asthma symptoms. As a part of the same scientific family, he mostly works in the field of Severe asthma, focusing on Phenotype and, on occasion, Immunology. As part of the same scientific family, Michael E. Wechsler usually focuses on Reslizumab, concentrating on Real world evidence and intersecting with Subgroup analysis and Environmental health.
His primary scientific interests are in Asthma, Internal medicine, Exacerbation, Immunology and Disease. His Asthma research incorporates elements of Hormone and Risk factor. His Internal medicine study combines topics in areas such as Gastroenterology and Inhalation.
His research in Exacerbation intersects with topics in Rate ratio, Poisson regression and Clinical research. The concepts of his Immunology study are interwoven with issues in Expression quantitative trait loci and Respiratory epithelium. His research integrates issues of Lama, Overweight, Pediatrics, Cohort and Comorbidity in his study of Disease.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro;James Zangrilli;Michael E Wechsler;Eric D Bateman.
The Lancet Respiratory Medicine (2015)
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: A multicenter, randomized, double-blind, sham-controlled clinical trial
Mario Castro;Adalberto S. Rubin;Michel Laviolette;Jussara Fiterman.
American Journal of Respiratory and Critical Care Medicine (2010)
Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial
Elliot Israel;Vernon M. Chinchilli;Jean G. Ford;Homer A. Boushey.
The Lancet (2004)
Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma.
Yvonne J. Huang;Craig E. Nelson;Eoin L. Brodie;Todd Z. DeSantis.
The Journal of Allergy and Clinical Immunology (2011)
Tiotropium bromide step-up therapy for adults with uncontrolled asthma
Stephen P. Peters;Susan J. Kunselman;Nikolina Icitovic;Wendy C. Moore.
The New England Journal of Medicine (2010)
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Michael E. Wechsler;Praveen Akuthota;David Jayne;Paneez Khoury.
The New England Journal of Medicine (2017)
Daily versus As-Needed Corticosteroids for Mild Persistent Asthma
Homer A. Boushey;Christine A. Sorkness;Tonya S. King;Sean D. Sullivan.
The New England Journal of Medicine (2005)
Smoking Affects Response to Inhaled Corticosteroids or Leukotriene Receptor Antagonists in Asthma
Stephen C. Lazarus;Vernon M. Chinchilli;Nancy J. Rollings;Homer A. Boushey.
American Journal of Respiratory and Critical Care Medicine (2007)
Lipoxin A4 Regulates Natural Killer Cell and Type 2 Innate Lymphoid Cell Activation in Asthma
Cindy Barnig;Manuela Cernadas;Stefanie Dutile;Xiaoli Liu.
Science Translational Medicine (2013)
Pulmonary Infiltrates, Eosinophilia, and Cardiomyopathy Following Corticosteroid Withdrawal in Patients With Asthma Receiving Zafirlukast
Michael E. Wechsler;Erik Garpestad;Steven R. Flier;Olivier Kocher.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: